Engineered Extracellular Vesicles for Consistent Therapeutic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current regenerative therapies using cardiosphere-derived cells (CDCs) and mesenchymal stem cells (MSCs) face variability in potency, with unclear mechanisms driving their immune-modulatory and regenerative effects, particularly regarding the RNA cargo in extracellular vesicles (EVs), which limits the consistency and efficacy of their therapeutic applications.
Innovation Solution
Engineered extracellular vesicles are produced by genetically modifying cells to overexpress specific microRNAs (miRs) such as miR-345, miR-146a, and let-7b, and deplete miR-10b and miR-10a, resulting in higher concentrations of these miRs in the EVs, enhancing their immunomodulatory and regenerative capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cells are used for regenerative therapy, then therapeutic effects are achieved, but variability in potency and consistency of efficacy occur
Solution Approach 1:
The patent changes the RNA cargo composition parameters of extracellular vesicles by genetically modifying cells to overexpress specific microRNAs (miR-345, miR-146a, let-7b) and deplete others (miR-10b, miR-10a). This standardizes the therapeutic payload across different cell batches, resolving the variability in potency while maintaining consistent regenerative and immunomodulatory effects.
Solution Approach 2:
The patent uses extracellular vesicles as intermediaries to deliver engineered RNA cargo to target tissues. These vesicles serve as standardized carriers that mediate the therapeutic effect, separating the variable cell source from the consistent therapeutic payload, thereby improving reliability while allowing flexibility in cell derivation.
2Productivity
If natural RNA cargo is used in extracellular vesicles, then immunomodulatory effects are achieved, but insufficient regenerative capability occurs
Solution Approach 1:
The patent creates composite RNA cargo within extracellular vesicles by combining multiple engineered microRNAs (miR-345, miR-146a, let-7b for regeneration; miR-10b, miR-10a depletion for immunomodulation). This composite approach synergistically enhances both regenerative capability and immunomodulatory efficacy, overcoming the limitations of natural single-cargo vesicles.
3Ease of manufacture
If cell therapy is applied, then tissue repair is achieved, but unclear mechanisms limit therapeutic optimization
Solution Approach 1:
The patent extracts and identifies the specific RNA cargo components (microRNAs) that mediate therapeutic effects from complex cell therapies. By isolating these key molecular players, the mechanism becomes understandable and controllable, enabling rational optimization of cell therapy manufacturing while maintaining ease of production through genetic modification of standard cell lines.
Data Source
AI summary
The present invention provides extrcellular vesicles, such as exosomes, engineered to be loaded with miR-345, which may be further loaded with, e.g., miR-146a and let-7b, and/or further be depleted of miR-10a and/or miR-10b. The present invention also provides an assay method, wherein the amounts of miR-345, miR146a, and let-7b in a sample of extracellular vesicles are positively associated with potency, and wherein the amount of miR-10b in a sample of extracellular vesicles is negatively associated with potency.